Tryptamine Therapeutics announced that it’s advancing to Phase 2 clinical trials for TRP-8803 – a scalable psilocin-based IV-infusion with potential neuroplasticity benefits.

The company claims TRP-8803 boasts a number of advantages over oral psilocybin dosing, including faster onset (under 20 minutes) with precise control of the depth and duration to the psychedelic state in a commercially feasible time frame. Also worth noting is that with TRP-8803, a treatment can be quickly halted if a patient is experiencing an adverse reaction. Here’s more: https://www.proactiveinvestors.com.au/companies/news/1060916/tryptamine-therapeutics-will-advance-to-trp-8803-psilocin-phase-2-clinical-trials-1060916.html

Cybin, Inc. announced 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program designed to treat major depressive disorder (MDD).

The company previously reported response and remission rates of 75% at four months. By the 12-month mark, response rates improved to 100% while 71% of participants were still in remission. No new adverse reactions were reported in the 12-month follow up.

Cybin has been able to move rapidly on these studies as a result of the FDA approving “Breakthrough Therapy Designation” for its potential treatment of MDD.  Check it out: https://www.businesswire.com/news/home/20241118852918/en/Cybin-Reports-Positive-Phase-2-Data-for-CYB003-Demonstrating-Breakthrough-12-Month-Efficacy-in-Treating-Major-Depressive-Disorder

A bipartisan panel of Georgia lawmakers endorsed a plan recommending the state spend up to $5 million studying the effects of MDMA and psilocybin on mental health treatments for military veterans. The proposal was one of 16 recommendations from the Senate Study Committee on Veterans, Mental Health and Housing.

While the committee’s recommendation was a first for Georgia, in order for the proposal to gain adoption, a budget allocation has to be vetted and approved by the General Assembly. Here’s more: https://medicalxpress.com/news/2024-11-georgia-lawmakers-funding-psychedelics-veterans.html

Did you know that ancient Egyptians drank hallucinogenic cocktails?

If you’re a regular reader of these pages, you probably did know that.  But a University of South Florida professor, Dr. Davide Tanasi, recently found the first-ever physical evidence of these hallucinogens in an Egyptian mug, validating written records of ancient Egyptian rituals and practices that included hallucinogenic cocktails.

Through advanced chemical analyses, Dr. Tanasi examined one of the world’s few remaining Egyptian Bes mugs.

These Bes mugs were decorated with the head of Bes, which was an ancient Egyptian god or guardian demon worshiped for protection, fertility, medicinal healing and magical purification.

Researchers performed a chemical and DNA analysis on the inner walls of the mug and revealed it contained a cocktail of psychedelic drugs, bodily fluids and alcohol – a combination that Tanasi believes was used in a magical ritual reenacting an Egyptian myth, likely for fertility. The concoction was flavored with honey, sesame seeds, pine nuts, licorice and grapes, which were commonly used to make the beverage look like blood. Tasty!  Here’s more: https://www.nature.com/articles/s41598-024-78721-8